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Plasma protein thiol oxidation and carbonyl formation in chronic Many patients with chronic renal failure (CRF), espe-
renal failure. cially those receiving maintenance dialysis therapy, exist
Background. Myeloperoxidase-catalyzed oxidative pathways in a chronic inflammatory state [1–12]. Patients with CRFhave recently been identified as an important cause of oxidant
are also subject to increased oxidative stress and maystress in uremia and hemodialysis (HD), and can lead to plasma
have decreased antioxidant defenses [13–20]. It has re-protein oxidation. We have examined patterns of plasma pro-
tein oxidation in vitro in response to hydrogen peroxide (H2O2) cently been suggested that the combination of chronic
and hypochlorous acid (HOCl). We measured thiol oxidation, inflammation and oxidant exposure may contribute to
amine oxidation, and carbonyl concentrations in patients on the high rate of cardiovascular disease in this patientchronic maintenance HD compared with patients with chronic
population [21].renal failure (CRF) and normal volunteers. We have also exam-
At the present time, the specific biochemical pathwaysined the effect of the dialysis procedure on plasma protein oxida-
tion using biocompatible and bioincompatible membranes. by which patients with renal failure are subjected to
Methods. Plasma proteins were assayed for the level of free increased oxidative stress are unclear. The relative im-
thiol groups using spectrophotometry, protein-associated car-
portance of the uremic state versus the role of renalbonyl groups by enzyme-linked immunosorbent assay, and oxi-
replacement therapy in exacerbating or ameliorating oxi-dation of free amine groups using a fluorescent spectropho-
tometer. dant stress has not been clarified. Studies examining lipid
Results. In vitro experiments demonstrate HOCl oxidation peroxidation as well as both intracellular and extracellu-
of thiol groups and increased carbonyl formation. In vivo, there lar antioxidant potential in the plasma of patients with
are significant differences in plasma-free thiol groups between
renal failure compared with normal controls have notnormal volunteers (279 6 12 mmol/L), CRF patients (202 6
always produced uniform results [22–26]. Miyata et al20 mmol/L, P 5 0.005) and HD patients (178 6 18 mmol/L,
P 5 0.0001). There are also significant differences in plasma have recently noted that some measures of oxidative
protein carbonyl groups between normal volunteers (0.76 6 stress such as carbonyl formation in lipids and carbohy-
0.51 mmol/L), CRF patients (13.73 6 4.45 mmol/L, P 5 0.015), drates could either be the result of oxidative reactionsand HD patients (16.95 6 2.62 mmol/L, P 5 0.0001). There
or of other nonenzymatic biochemical pathways [27].are no significant differences in amine group oxidation. HD
It has long been recognized that patients on chronicwith both biocompatible and bioincompatible membranes re-
stored plasma protein thiol groups to normal levels, while mini- hemodialysis (HD) therapy may be subjected to the con-
mally affecting plasma protein carbonyl expression. sequences of excessive phagocytic cell activation [28].
Conclusions. First, both CRF and HD patients have in- Neutrophils from patients with CRF are primed for thecreased plasma protein oxidation manifested by oxidation of
respiratory burst in response to receptor-mediated stimulithiol groups and formation of carbonyl groups. Second, HD
such as N-formyl-methionyl-leucyl-phenyalanine (FMLP)with biocompatible and bioincompatible membranes restored
plasma protein thiol groups to normal levels. Third, these ex- [29]. Products of neutrophil degranulation, including my-
periments suggest that there is a dialyzable low molecular eloperoxidase (MPO) and elastase, are elevated in the
weight toxin found in uremia that is responsible for plasma
serum of chronic HD patients as compared with normalprotein oxidation.
controls [30–32]. Furthermore, patients on chronic HD,
especially when dialyzed using unmodified cellulosic
membranes, develop activation of the alternative path-
way of complement, increased neutrophil reactive oxy-Key words: hemodialysis, uremia, oxidant stress, thiol, carbonyl, bio-
compatibility. gen species production, and degranulation [33].
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Himmelfarb et al, J Am Soc Nephrol 10:283A, 1999). To from the initial line placement before a heparin bolus
was given. Samples were then drawn from the efferentexplore further whether MPO-catalyzed reactions may
contribute to oxidative stress in renal failure, we exam- line at 15, 60, and 240 minutes (end) of the dialysis
treatment. For examination of postdialysis rebound,ined patterns of plasma protein oxidation in vitro in
response to the phagocyte-derived oxidants hydrogen samples were taken from three HD patients 30 and 60
minutes after the conclusion of dialysis. All patients wereperoxide (H2O2) and hypochlorous acid (HOCl). We also
examined plasma protein oxidation in patients on chronic routinely receiving treatment with high-flux polysulfone
membranes prior to the study. A bicarbonate-based dial-maintenance HD compared with patients with CRF not
on renal replacement therapy and to normal controls. ysate and routine heparinization were used in all studies.
Patients were studied using first use cellulosic, hollow-The effect of the dialysis procedure on plasma protein
oxidation was also studied using both biocompatible and fiber dialyzers or first use high-flux, synthetic dialyzers.
bioincompatible membranes.
Assay for free sulfhydryl groups
Free sulfhydryl groups were assayed according to the
METHODS
method of Ellman [34] as modified by Hu [35]. Briefly,
Reagents 1 mL of buffer containing 0. 1 mol/L Tris, 10 mmol/L
EDTA, pH 8.2, and 50 mL plasma were added to cu-Fluorescamine, 5959dithio-bis(2-nitrobenzoic acid)
(DTNB), o-phenylenediamine (OPD), 2,4-dinitrophenyl- vettes, followed by 50 mL 10 mmol/L DTNB in methanol.
Blanks were run for each sample, prepared as describedhydrazine (DNPH), hypochlorous acid, and hydrogen
peroxide were obtained from Sigma Chemical Co. (St. previously in this article, with the exception that there
was no DTNB in the methanol. Following incubationLouis, MO, USA). The Bio-Rad Protein Assay was pur-
chased from Bio-Rad Laboratories (Hercules, CA, USA), for 15 minutes at room temperature, sample absorbance
was read at 412 nm on a Lambda 2 spectrophotometerand Nunc Maxisorp microtiter plates were purchased
from USA/Scientific Plastics (Ocala, FL, USA). Enzyme- (Perkin Elmer, Norwalk, CT, USA). Sample and reagent
blanks were also subtracted. The concentration of sulf-linked immunosorbent assay (ELISA) reagents antidi-
nitrophenyl-KLH-biotin conjugate and streptavidin-bio- hydryl groups was determined using the TNB molar ex-
tinction coefficient of 14,100 M21 cm21, and results aretinylated horseradish peroxidase complex were purchased
from Molecular Probes (Eugene, OR, USA) and Amer- reported as micromoles per liter (mmol/L) [36]. The coef-
ficient of variation for this assay was 2.67%.sham Pharmacia Biotech (Piscataway, NJ, USA), respec-
tively. Although theoretically in vivo generation of long-lived
oxidants such as N-chloramines could biochemically con-
Patient characteristics vert TNB to DTNB, previous work by Hu et al and van
der Vliet has demonstrated that this should not interfereTen patients on chronic maintenance HD, 10 patients
with CRF not receiving renal replacement therapy (CRF), with detection of free sulfhydryl groups using this assay
[35, 37].9 patients receiving peritoneal dialysis therapy (PD), and
10 normal controls were selected for each part of the study.
ELISA for protein-associated carbonyl groupsFor CRF patients, the mean serum creatinine was 4.3 6
0.3 mg/dL, and creatinine clearance was 22 6 2 mL/min. Carbonyl groups were assayed by ELISA according
to the method of Buss et al [38] as amended by Win-Informed consent was obtained from all subjects, and
the protocol was approved by the Institutional Review terbourn and Buss [39]. Oxidized protein standards were
prepared from bovine serum albumin (BSA) oxidized withBoard.
HOCl or reduced with sodium borohydride, and assayed
Samples for carbonyl content using the colorimetric method of
Levine et al [40]. Standards and samples were assayedFor in vitro studies, blood was drawn into Vacutainer
tubes containing heparin for treatment with oxidants or for protein content (Bio-Rad Protein Assay) and diluted
to 4 mg/mL, and a standard curve was generated fromcontaining ethylenediaminetetraacetic acid (EDTA) for
controls. Oxidants HOCl and H2O2 were added to whole the BSA standards. In a 1.5 mL microcentrifuge tube,
15 mL aliquots of samples and standards were derivatizedblood at 10 mmol/L final concentration and incubated
at 378C for 30 minutes. Blood was centrifuged at 1700 3 g with 45 mL 10 mmol/L DNPH in 6 mol/L guanidine HCl
0.5 mol/L potassium phosphate buffer, pH 2.5. Tubesfor 15 minutes to obtain plasma.
For in vivo studies, blood was drawn into Vacutainer were incubated for 45 minutes at room temperature with
additional vortexing every 10 to 15 minutes. A 5 mL ali-tubes containing EDTA supplemented with 1000 IU/mL
catalase and centrifuged at 1700 3 g for 15 minutes to quot of each tube was diluted in 1 mL phosphate-buffered
saline (PBS); 200 mL of each sample or standard wasobtain plasma for assays. For intradialytic studies, blood
was drawn at the beginning of the dialysis treatment added to triplicate microliter plate wells (Nunc Maxisorp),
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Fig. 1. In vitro plasma protein oxidation by hydrogen peroxide (H2O2) Fig. 2. In vivo plasma protein thiol oxidation. *P , 0.05 vs. normal
and hypoclorous acid (HOCl). Whole blood from four normal volun- volunteers (N 5 10 in each group).
teers was treated with 10 mmol/L H2O2 or HOCl and is reported as a
percentage of values for untreated control. *P , 0.05 vs. untreated
control. Symbols are: (j) untreated controls; ( ) H2O2 treated; (h)
HOCl treated.
and the plate was incubated at 48C overnight. Plates Results are reported as fluorescence intensity (FI). The
coefficient of variation for this assay was 4.9%.were incubated for 1.5 hours at room temperature in
blocking buffer (0. 1% Tween 20 in PBS) using 250 mL
Statisticsper well. Plates were washed five times with PBS, coated
Data were analyzed using analysis of variancewith 200 mL per well anti-DNP-biotin conjugate diluted
(ANOVA) and Student’s t-tests. Results are reported as1:1000 in blocking buffer, and incubated at 378C for one
mean 6 SEM.hour. Following another 5 3 wash with PBS, 200 mL
streptavidin-biotinylated horseradish peroxidase 1:3000
RESULTSin blocking buffer was added followed by one hour of
incubation at room temperature. After the final wash in In vitro plasma protein oxidation: Effects of HOCl
PBS, 200 mL of substrate (0.6 mg/mL OPD, 0.012% H2O2 versus H2O2
in 50 mmol/L phosphate 24 mmol/L citric acid, prepared We compared the effects of 10 mmol/L exogenous
immediately before use) were added to each well, and hypochlorous acid and hydrogen peroxide on plasma
the color was developed for 25 minutes before 100 mL protein oxidation in three assays selected to measure thiol,
per well 2.5 mol/L sulfuric acid was added to stop the free amine, and carbonyl concentrations (Fig. 1). While
reaction. Absorbance was read at 490 nm on a Vmax both species significantly decreased free thiols and amines,
microtiter plate reader (Molecular Devices, Sunnyvale, it is clear from Figure 1 that HOCl was a much more
CA, USA). The oxidized BSA standard curve was plot- potent oxidant than H2O2. The addition of 10 mmol/L
HOCl to normal blood resulted in a decrease in thiolted, and values for samples were read off the curve.
concentration to 3 6 3% (P , 0.0001) that of controls.While results from this assay are usually reported as
Treatment with 10 mmol/L H2O2 resulted in a significantnmol/mg protein, for comparison with thiol data, the
but relatively modest decrease to 70 6 8% (P 5 0.03)carbonyl data have been converted to mmol/L by using
in thiol concentration compared with controls. Aminethe total protein content of each sample, as determined
groups were oxidized to 72 6 2% (P 5 0.0005) of controlsin the Bio-Rad protein assay. The results are reported
by 10 mmol/L HOCl and to 86 6 3% (P 5 0.013) ofas mol/L or mmol/L. The coefficient of variation for this
controls by 10 mmol/L H2O2. The third measure of pro-assay was 4.4%.
tein oxidation used for in vitro studies was carbonyl
formation, which increases as proteins are oxidized.Assay for free amine groups
Therefore, the change in carbonyl concentration is on
To determine the concentration of amine groups, we a different scale, found on the right axis of Figure 1.
used a fluorometric method described by Bohlen et al Treatment with 10 mmol/L HOCl resulted in a 712 6
[41] and adapted by Davies, Delsignore, and Lin [42] and 62% (P 5 0.0001) increase in carbonyl groups, while
Arnhold et al [43]. Using glass tubes, we added 10 mL treatment with 10 mmol/L H2O2 increased carbonyl
plasma to 2.5 mL 0.05 mol/L phosphate buffer, pH 8.0. groups only 6 6 7% (P 5 0.455) compared with controls.
While vortexing, we added 0.5 mL fluorescamine (Sigma
In vivo plasma protein thiol oxidationF-9015) at 0.4 mg/mL in acetone. Samples were read on
an F-2000 fluorescence spectrophotometer (Hitachi, San To examine in vivo plasma protein oxidation, we mea-
sured free thiol levels in CRF and HD patients comparedJose, CA, USA) at excitation 390 nm and emission 475 nm.
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Fig. 4. In vivo plasma protein amine oxidation. There were no signifi-
Fig. 3. In vivo plasma protein carbonyl formation. *P , 0.05 vs. normal cant differences between groups (N 5 10 for each group).
volunteers (N 5 10 in each group).
with normal volunteers. Figure 2 demonstrates signifi- membranes at each time point. The predialysis thiol con-
centration was 172 6 12 mmol/L for PS versus 178 6cant differences in plasma free thiol groups between
18 mmol/L for CU. At the 15-minute time point, thiolsnormal volunteers (279 6 12 mmol/L) and patients with
were at 196 6 10 mmol/L for PS versus 197 6 14 mmol/LCRF (202 6 20 mmol/L, P 5 0.005 vs. normal volunteers)
for CU. After 60 minutes of dialysis, thiol groups mea-and patients receiving chronic HD therapy (178 6
sured 190 6 21 mmol/L for PS versus 202 6 16 mmol/L18 mmol/L, P 5 0.0001 vs. normal volunteers). There
for CU. At the conclusion of the dialysis session, thiolwere no significant differences between CRF patients
levels had risen to 266 6 10 mmol/L for PS versus 273 6and chronic HD patients in the level of free plasma thiol
22 mmol/L for CU.groups (P 5 0.36). We also measured free thiol levels
A comparison of thiol levels between time points re-in nine patients on peritoneal dialysis. The results (215 6
vealed that for both membranes the concentration of19 mmol/L) were significantly different from normal vol-
thiol groups increased such that levels at the conclusionunteers (P 5 0.011) but not from patients with CRF
of the dialysis sessions were significantly higher than at(P 5 0.64) or patients receiving HD therapy (P 5 0.15).
all other time points. Indeed, by the conclusion of the
In vivo plasma protein carbonyl formation dialysis sessions, the thiol concentration had reached
the level seen in normal volunteers (Fig. 2). For the PSFigure 3 demonstrates significant differences in the
membrane, the P value for analysis of variance waslevel of plasma protein carbonyl groups between normal
0.0001 followed by t tests of significance for end of dial-volunteers (0.76 6 0.51 mmol/L) and CRF patients
ysis versus predialysis (P 5 0.0001), versus 15 minutes(13.73 6 4.45 mmol/L, P 5 0.015 vs. normal volunteers)
(P 5 0.0013), and versus 60 minutes (P 5 0.015). Forand HD (16.95 6 2.62 mmol/L, P 5 0.0001 vs. normal
the CU membrane, the P value for overall ANOVA wascontrols). There was no significant difference in the
0.0031, and t-tests showed significance for end of dialysisplasma protein carbonyl group concentration between
versus predialysis (P 5 0.005), versus 15 minutes (P 5CRF patients and chronic HD patients (P 5 0.64).
0.017), and versus 60 minutes (P 5 0.004).
In vivo plasma protein amino group oxidation
Examination of plasma protein oxidation postdialysis
Figure 4 demonstrates that there were no significant
To determine whether there are significant intracellu-differences in oxidation of plasma protein free amine
lar stores of oxidized proteins that might equilibrate withgroups between normal volunteers (2191 6 45 FI) and
plasma proteins, we examined levels of plasma protein-CRF patients (2062 6 51 FI) or chronic HD patients
free thiol groups and plasma protein carbonyls in three(2113 6 94 FI).
patients at 30 and 60 minutes after the end of HD. There
were no significant differences either in the content ofEffects of hemodialysis on plasma protein
plasma protein carbonyl groups or free thiol groups atthiol oxidation
either 30 or 60 minutes after the end of dialysis compared
To determine the effect of the dialysis procedure on with the end of dialysis (data not shown). Thus, there
plasma protein thiol oxidation, comparisons were made does not appear to be a postdialysis oxidation rebound.
of intradialytic plasma protein thiol content using a high-
flux, biocompatible dialysis membrane (PS) (Fig. 5) and
DISCUSSIONa low-flux, bioincompatible dialysis membrane (CU;
Fig. 6). Changes in plasma protein thiol concentrations Patients with CRF, especially when they require main-
tenance dialysis therapy, experience excessively high car-were very similar in samples from the different dialysis
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Fig. 5. Plasma protein thiol oxidation during HD with biocompatible Fig. 6. Plasma protein thiol oxidation during HD with bioincompatible
membranes. *P , 0.05 vs. all other time points (N 5 10 HD patients). membranes. *P , 0.05 vs. all other time points (N 5 10 HD patients).
diovascular morbidity and mortality. Even after adjust- Because of the limitations in studies measuring plasma
LDL peroxidation, we have chosen to examine plasmament for age, gender, race, and the presence or absence
of diabetes, cardiovascular mortality has been reported protein oxidation as a measure of oxidative stress in
patients with CRF. We have used three separate assaysto be 10-fold to 20-fold higher than in the general popula-
tion [44]. Furthermore, risk factors for cardiovascular to examine plasma protein oxidation in patients with
CRF and chronic HD patients. We have demonstrateddisease differ between the general population and pa-
tients with chronic renal disease, suggesting that proc- that both groups of patients have marked plasma protein
thiol oxidation, marked plasma protein carbonyl forma-esses related to either uremia per se and/or the dialysis
procedure may contribute in unique ways to cardiovascu- tion, and no evidence of plasma protein amino group
oxidation. This pattern of plasma protein oxidation inlar complications [21].
One postulated mechanism by which patients with CRF patients with CRF is similar to the demonstrated in vitro
effects of hypochlorous acid on normal plasma protein.may develop accelerated atherogenesis and cardiovascular
complications is through chronic inflammation leading These findings are in concordance with recent work from
our laboratory demonstrating elevated levels of 3-chlo-to increased exposure to oxidant stress. There is now
considerable evidence linking both inflammation and ox- rotyrosine in plasma protein in chronic HD patients,
confirming the role of MPO catalyzed chlorinating oxida-idative stress with the pathogenesis of atherosclerosis.
In particular, oxidation of low-density lipoprotein (LDL) tive reactions in contributing to oxidative stress in pa-
tients with renal failure (abstract; Himmelfarb et al, J Amallows LDL to be taken up by monocyte/macrophage
scavenger receptors, a process that ultimately leads to Soc Nephrol 10:283A, 1999).
Heinecke has recently emphasized the potential rolefoam cell and fatty streak formation [45]. Several previ-
ous investigators have measured lipid peroxidation in the of MPO-catalyzed oxidation in contributing to the devel-
opment of atherosclerosis [53, 54]. These investigatorsplasma or in erythrocyte membranes of patients with CRF
on dialysis as a measure of oxidant stress. While some found catalytically active MPO in human atherosclerotic
tissue, colocalized with foamy macrophages [55]. Bothstudies have demonstrated an increase in lipid peroxidation
products in HD patients compared with normal controls dityrosine and 3-chlorotyrosine, potential MPO-catalyzed
end products of tyrosine oxidation, have been found in[22, 26, 46–50], this finding has not been uniformly repro-
ducible [23–25, 51]. Similarly, while some studies have oxidatively modified LDL [56] and in human atheroscle-
rotic lesions [57]. Nguyen-Khoa et al have recently showndemonstrated a decreased lag time for copper-induced
LDL oxidation in vitro (a commonly used measure of that HOCl-modified LDL increases monocyte oxidative
metabolism [58]. These investigators have also suggestedresistance to oxidant stress) in patients on HD [26], other
studies have not been able to confirm these findings (ab- that MPO-catalyzed reactions may be the predominant
form of excess oxidative metabolism in patients withstract; O’Bryne et al, Baxter Extramural Grant Program,
Annual Meeting 27, 1998) [24]. The variability in the results CRF and in patients receiving dialysis therapy.
Other investigators have examined plasma protein ox-of studies of lipid peroxidation as a measure of oxidative
stress in chronic HD patients may be due to the short idation in patients with CRF. In a series of studies, Mi-
yata et al have examined the formation of carbonyl groupsplasma half-lives of lipid peroxidation products. Also,
the most important lipid oxidation may take place in the in amino acids, lipids, and carbohydrates in patients with
CRF as a measure of oxidative stress and have usedvessel wall intima and not in the plasma. Alternatively,
if the major source of increased oxidant stress in patients the term “carbonyl stress” [27]. Our data confirm the
development of plasma protein carbonyl formation inwith CRF is MPO catalyzed reactions, then lipid peroxi-
dation may not be the major oxidative end product [52]. patients with CRF, but suggest that oxidative stress in
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renal failure is more generalized. The data in our study relatively short exposure to high levels of oxidants pro-
duced during HD with bioincompatible membranes. Al-suggest that “thiol stress” may be quantitatively more
important than “carbonyl stress” in CRF patients. Fur- ternatively, HD bioincompatibility could contribute to
higher levels of oxidant injury in the vascular wall be-thermore, thiol stress may be more reversible and treat-
able than carbonyl stress in CRF patients. While alde- cause of leukocyte endothelial cell adhesion, with less
obvious changes in plasma protein oxidation [59–62].hyde binding to thiol groups could account for both thiol
oxidation and carbonyl formation, quantitatively most In summary, patients with CRF develop increased lev-
els of plasma protein oxidation, likely as a consequenceof the plasma protein thiol group oxidation cannot be
accounted for by measured levels of carbonyl formation of oxidant stress. The phenomenon of plasma protein
oxidation in patients with CRF may result from inflam-in this study. Since most plasma-free thiol groups are
found in albumin, these results suggest that albumin may mation, phagocytic cell oxidation, and consequent MPO-
catalyzed oxidation. Oxidation of plasma thiol groups,be a major oxidation target in uremia. To the extent that
“thiol stress” contributes to the pathogenesis of cardio- located largely on albumin, is quantitatively the major
manifestation of protein oxidation. HD, whether with cel-vascular disease in this patient population, new therapeu-
tic possibilities (such as oral or intravenous administra- lulosic or synthetic membranes, improves “thiol stress” in
tion of reduced sulfhydryl groups) could be envisioned. patients with CRF. These and other studies suggest the
An important finding in this article is that levels of presence of a dialyzable, low molecular weight substance
“thiol stress” improved dramatically in chronic mainte- in the plasma of patients with CRF. Further research is
nance HD patients over the course of the dialysis proce- required to identify oxidizing substances in uremia and
dure. In contrast, levels of detectable carbonyl groups to develop therapeutic strategies to reduce oxidant stress
did not change over the dialysis period, likely as a result in this patient population. Further research is also re-
of the irreversability of the chemical reactions that re- quired to understand the potential linkage between oxi-
sult in carbonyl formation. Restoration of thiol groups dant stress and cardiovascular complications in patients
occurs with a similar time course whether patients are with CRF.
dialyzed with low-flux, bioincompatible cellulosic mem-
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